文献速递神经免疫

芬戈莫德与富马酸二甲酯治疗多发性硬化:真实世界倾向评分匹配研究

Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
PubMed 文献 · Neurology · 2018-06-06

在意大利中部7家多发性硬化门诊中,比较芬戈莫德(FNG)与富马酸二甲酯(DMF)对复发缓解型多发性硬化(RRMS)患者无疾病活动证据(NEDA-3)状态的影响。倾向评分匹配后每组275例,中位随访18个月,NEDA-3比例FNG 73% vs DMF 70%(HR 0.74,p=0.078),无显著差异;亚组分析显示切换者中FNG优于DMF(HR 0.57,p=0.007),初治者中两者相当(HR 1.15,p=0.689)。

要点

  • 匹配后FNG组与DMF组NEDA-3比例相似(73% vs 70%,HR 0.74,p=0.078)。
  • 切换者亚组中FNG优于DMF达成NEDA-3(HR 0.57,p=0.007)。
  • 初治者亚组中两药疗效相当(HR 1.15,p=0.689)。

核心结论

  • FNG与DMF在NEDA-3状态上无显著差异,亚组分析提示切换自自我注射药物的患者中FNG优于DMF。

研究设计与样本

  • 研究纳入意大利中部7家多发性硬化门诊的RRMS患者,比较FNG与DMF作为首次治疗或切换自自我注射药物后的疗效。
  • 采用倾向评分(PS)最邻近匹配(卡钳值0.05)选取基线特征同质的患者,并进行配对删失以调整两组随访时间差异。
  • 匹配样本中使用以中心分层的Cox模型比较NEDA-3(主要结局),NEDA-3定义为无复发、无残疾恶化且无MRI活动。
  • 共有483例和456例患者分别开始FNG和DMF并符合分析条件,PS匹配后保留550例(每组275例)。

主要发现

  • 中位研究随访18个月后,NEDA-3患者比例FNG组73% vs DMF组70%(HR 0.74,p=0.078)。
  • 初治者亚组(n=170)中两药疗效相当(HR 1.15,p=0.689)。
  • 切换者亚组(n=380)中FNG优于DMF达成NEDA-3(HR 0.57,p=0.007)。

关键数值与推荐

  • NEDA-3定义为无复发、无残疾恶化且无MRI活动。
  • 匹配卡钳值为0.05。

临床怎么用

  • 作者认为,对于RRMS患者,DMF与FNG在初治患者中疗效相当,而在切换自自我注射药物的患者中FNG优于DMF。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To directly compare fingolimod (FNG) and dimethyl fumarate (DMF) on no evident disease activity (NEDA) status in patients with relapsing-remitting multiple sclerosis (RRMS) from 7 multiple sclerosis outpatient clinics in Central Italy. METHODS: We analyzed data of patients with RRMS who started an oral agent, namely DMF or FNG, either as first treatment (naives) or after switching from self-injectable drugs (switchers). We performed a propensity score (PS)-based nearest-neighbor matching within a caliper of 0.05 to select patients with homogeneous baseline characteristics. Pairwise censoring was adopted to adjust for difference in length of follow-up between the 2 treatment groups. Comparisons were then conducted in matched samples with Cox models (stratified by center) with NEDA-3 as the main outcome. NEDA-3 was defined as no relapses, no disability worsening, and no MRI activity. RESULTS: Overall, 483 and 456 patients eligible for analysis started on FNG and DMF, respectively. The PS-matching procedure retained a total of 550 patients (275 per group). After a median on-study follow-up of 18 months, the proportions of patients with NEDA-3 were similar (FNG 73%, DMF 70%; hazard ratio [HR] 0.74, p = 0.078). Subgroup analyses showed a comparable effectiveness of the 2 drugs in naives (n = 170, HR 1.15, p = 0.689), whereas FNG was superior to DMF in the achievement of NEDA-3 status among switchers (n = 380, HR 0.57, p = 0.007). CONCLUSION: We found no significant difference between FNG and DMF on NEDA-3 status, while subgroup analyses suggest the superiority of FNG over DMF in patients switching from self-injectable drugs. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with RRMS, DMF and FNG have comparable efficacy in treatment-naive patients and that FNG is superior to DMF in patients switching from self-injectable drugs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Prosperini L, Lucchini M, Haggiag S, et al. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study. Neurology. 2018. PMID: 29875218. doi:10.1212/WNL.0000000000005772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。